CervoMed (CRVO) announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Before joining CervoMed, Dr. Winton served as COO at Inozyme Pharma (INZY).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed announces development program, benefits of neflamapimod
- H.C. Wainwright sets CervoMed price target into FDA clarity
- CervoMed price target raised to $31 from $15 at D. Boral Capital
- CervoMed’s Promising Developments and Financial Stability Drive Buy Rating with $20 Price Target
- CervoMed price target lowered to $16 from $20 at Roth Capital